What Vestal Point Capital, LP reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 1974915 · Filed Nov 16, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 2.5M |
| +33.0% |
| $354.6M |
| 9.2% |
BMRNBioMarin Pharmaceutical Inc | 5.5M | −8.3% | $331.5M | 8.6% |
ARWRArrowhead Pharmaceuticals, Inc. | 4.8M | +205.7% | $315.1M | 8.1% |
INSMInsmed Inc | 2.7M | +990.0% | $311M | 8% |
UTHRUnited Therapeutics Corp | 475K | +9.2% | $257.4M | 6.6% |
ASNDAscendis Pharma A/S | 740K | +97.3% | $168.6M | 4.4% |
NRIXNurix Therapeutics, Inc. | 7M | −12.7% | $166.6M | 4.3% |
TARSTarsus Pharmaceuticals, Inc. | 2M | +93.7% | $159.9M | 4.1% |
ELVNEnliven Therapeutics, Inc. | 3.2M | −19.4% | $147.8M | 3.8% |
IRONDisc Medicine, Inc. | 1.6M | +5.5% | $107M | 2.8% |
BCAXBicara Therapeutics Inc. | 5.5M | +5.2% | $102.8M | 2.7% |
DYNDyne Therapeutics, Inc. | 6.2M | +83.7% | $99.9M | 2.6% |
IMTXImmatics N.V. | 11.2M | +81.4% | $98.3M | 2.5% |
TSHATaysha Gene Therapies, Inc. | 18M | −7.1% | $87.9M | 2.3% |
GLUEMonte Rosa Therapeutics, Inc. | 7.1M | +55.0% | $85.1M | 2.2% |
GMEDGlobus Medical Inc | 915K | +7.6% | $68.5M | 1.8% |
CBIOCrescent Biopharma, Inc. | 3M | +84.0% | $43.8M | 1.1% |
ZBHZimmer Biomet Holdings, Inc. | 475K | −66.1% | $42.2M | 1.1% |
TVTXTravere Therapeutics, Inc. | 600K | New | $35.3M | 0.9% |
RCUSArcus Biosciences, Inc. | 1.3M | New | $33.6M | 0.9% |
XENEXenon Pharmaceuticals Inc. | 850K | +21.4% | $31.6M | 0.8% |
NKTRNektar Therapeutics | 510K | −49.0% | $30.9M | 0.8% |
DRUGBright Minds Biosciences Inc. | 545K | ±0% | $27.2M | 0.7% |
BBIOBridgeBio Pharma, Inc. | 400K | New | $26.3M | 0.7% |
IMCRImmunocore Holdings plc | 850K | −52.8% | $25.7M | 0.7% |
PODDInsulet Corp | 175K | −73.9% | $22.8M | 0.6% |
TRVITrevi Therapeutics, Inc. | 1.5M | −51.8% | $21.4M | 0.6% |
SNYSanofi | 500K | −75.0% | $20.6M | 0.5% |
SVRASavara Inc | 3.3M | +21.3% | $17M | 0.4% |
SGPSpyGlass Pharma, Inc. | 640K | −4.5% | $16.6M | 0.4% |
ZYMEZymeworks Inc. | 600K | New | $15.9M | 0.4% |
COGTCogent Biosciences, Inc. | 475K | New | $15.2M | 0.4% |
SLDBSolid Biosciences Inc. | 2.1M | −3.5% | $15.1M | 0.4% |
LXEOLexeo Therapeutics, Inc. | 4.3M | ±0% | $14.6M | 0.4% |
AVTXAvalo Therapeutics, Inc. | 800K | +3.2% | $12.3M | 0.3% |
ZBIOZenas BioPharma, Inc. | 395K | +8.2% | $10.7M | 0.3% |
EVMNEvommune, Inc. | 1.3M | +25.0% | $10.3M | 0.3% |
VKTXViking Therapeutics, Inc. | 290K | −57.4% | $9.5M | 0.2% |
STOKStoke Therapeutics, Inc. | 345K | New | $9M | 0.2% |
KRSAKorsana Biosciences, Inc. | 263.1K | New | $8.4M | 0.2% |
DMRADamora Therapeutics, Inc. | 395K | New | $8.4M | 0.2% |
TECXTectonic Therapeutic, Inc. | 360K | −15.3% | $8.4M | 0.2% |
ZURAZura Bio Ltd | 1.9M | +58.4% | $7.7M | 0.2% |
GKOSGlaukos Corp | 45K | New | $7.4M | 0.2% |
KLRAKailera Therapeutics, Inc. | 625K | +8.7% | $7.1M | 0.2% |
AVRAnteris Technologies Global Corp. | 850K | −15.8% | $6.6M | 0.2% |
MLTXMoonLake Immunotherapeutics | 525K | New | $6.1M | 0.2% |
RZLTRezolute, Inc. | 1.5M | +279.9% | $6M | 0.2% |
TRAXFirst Tracks Biotherapeutics, Inc. | 169.7K | −83.2% | $6M | 0.2% |
VYGRVoyager Therapeutics, Inc. | 2.2M | −17.5% | $5.8M | 0.1% |
MAZEMaze Therapeutics, Inc. | 175K | New | $4.8M | 0.1% |
OLMAOlema Oncology, Inc. | 420K | +0.3% | $3.6M | 0.1% |
PALIPalisade Bio, Inc. | 2.5M | ±0% | $3.4M | 0.1% |
ENGNenGene Therapeutics Inc. | 1.7M | −0.1% | $3.3M | 0.1% |
NGNENeurogene Inc. | 115K | New | $3.2M | 0.1% |
IBIOiBio, Inc. | 2.6M | ±0% | $3.1M | 0.1% |
AVBPArriVent BioPharma, Inc. | 100K | New | $3M | 0.1% |
OKUROnKure Therapeutics, Inc. | 1.1M | −40.4% | $3M | 0.1% |
CTMXCytomX Therapeutics, Inc. | 535K | New | $1.5M | 0.1% |
OCSOculis Holding AG | 132K | New | $1.2M | 0.1% |
NYXHNyxoah SA | 479K | −43.2% | $661K | 0.1% |
APREAprea Therapeutics, Inc. | 350K | ±0% | $262.5K | 0.1% |